GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, led a $30m series A round for US-based gene therapy developer Spotlight Therapeutics on Monday.
The corporate was joined by undisclosed other investors, the round coming in the wake of $7.3m in equity funding in January 2018 and $6.9m in September 2019, according to regulatory filings.
Spotlight is working on cell-targeted therapeutics for cancer and a class of blood disorders known as hemoglobinopathies. They will utilise Crispr gene editing technology and are being developed through its Targeted Active Gene Editor (TAGE) platform.
Company co-founder Alex Marson said: “Spotlight’s unique approach represents the potential to expand applications and democratise gene editing for patients.”
Mary Haak-Frendscho, Spotlight’s president and chief executive, added: “Having the support of top-tier investors like GV will be important as we continue to build the company and its programs to treat serious diseases.”
Blake Byers, general partner at GV, has taken a seat on the startup’s board of directors in conjunction with the round.
